Bio Saga Headlines

Bio Saga

Friday, May 18, 2012

Agilent to Acquire Dako for $2.2 Billion Acquisition is Next Step in Agilent's Growing Role in Clinical Diagnostics

Dako is one of the leading global providers of cancer diagnostics tools.

--Acquisition will strategically complement Agilent's research technologies and will accelerate growth in rapidly expanding segments of diagnostic markets.

--Significantly increases base of recurring revenues.

--All-cash deal is largest in Agilent's history.

Expected to be immediately accretive to Agilent earnings on a non-GAAP basis.
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, today announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent's history.

Dako's products are sold in more than 100 countries, and in 2010 its annual revenue was approximately $340 million (USD). The company employs more than 1,000 people, primarily in Denmark, in Carpinteria, Calif., and other parts of the world. The acquisition is expected to close within the next 60 days, subject to the satisfaction of customary closing conditions.

Life Science and Informatics

What is this?
is this a new industry?
or a old wine in a new bottle?

Well Life Sciences and Informatics can be anything form computational biology, all omes and omics, core bioinformatics to curation and literature mining, database creation, in the area of biology, chemistry , bio-chem space.

There are number of companies in India and bangalore is the forefront as a major bio-cluster with 20 to 30 companies in this sphere.

now how good are these companies doing?
how good are they in terms of the international markets and how profitable is their business?
what do they do?
their clients?

These are some interesting things that could be discussed in this blog page...

Tag It